Background: The efficacy of emotional disclosure in alleviating psychological and physical stress has been well documented in controlled laboratory studies. A next step is to evaluate its clinical utility in ‘real world’ settings. We adapted the emotional disclosure intervention for use in home-based settings by stimulating the suggested effective ingredients of cognitive-emotional processing, and evaluated its psychological and clinical effectiveness. Reviews indicated the need to examine the physiological changes brought about by emotional disclosure, which may be particularly relevant in immune-mediated diseases. This study was the first to examine neuroendocrine and immune changes after emotional disclosure in patients with rheumatoid arthritis. Methods: Sixty-eight patients were randomly assigned to four weekly oral emotional disclosure or time management sessions. At baseline and 1 week and 3 months after the sessions, depressed and cheerful mood, joint scores, erythrocyte sedimentation rate, cortisol, noradrenaline, interleukin-6 (IL-6), interferon-γ (IFN-γ), and IL-10 were evaluated. Repeated measures analyses of variance were performed. Results: No effect on psychological well-being and clinical outcome was found (p ≥ 0.10). Cortisol (p = 0.01) and the serum level of the pro-inflammatory cytokine IFN-γ (p = 0.05) were differentially affected by the two conditions. The change of IL-6 nearly reached significance (p = 0.07). Conclusions: The physiological changes are in agreement with theories on the mechanisms underlying emotional disclosure benefits and are suggestive of better disease control after emotional disclosure. General and study-specific reasons for the absence of psychological and clinical effects are discussed. The findings warn against widespread implementation of this home-based emotional disclosure intervention in unselected rheumatoid arthritis samples.

Keywords:
Rheumatoid arthritis, Emotion regulation, Emotional disclosure, Erythrocyte sedimentation rate, Joint count, Noradrenaline, Cortisol, Cytokines, Interleukin-6, Randomized clinical trial
1.
Pennebaker JW, Beall SK: Confronting a traumatic event: toward an understanding of inhibition and disease. J Abnorm Psychol 1986;95:274–281.
2.
Frisina PG, Borod JC, Lepore SJ: A meta-analysis of the effects of written emotional disclosure on the health outcomes of clinical populations. J Nerv Ment Dis 2004;192:629–634.
3.
Smyth JM: Written emotional expression: effect sizes, outcome types, and moderating variables. J Consult Clin Psychol 1998;66:174–184.
4.
Smyth JM, Catley D: Translating research into practice: potential of expressive writing in the field; in Lepore SJ, Smyth JM (eds): The Writing Cure: How Expressive Writing Promotes Health and Emotional Well-Being. Washington, American Psychological Association, 2002, pp 199–214.
5.
Broderick JE, Stone AA, Smyth JM, Kaell AT: The feasibility and effectiveness of an expressive writing intervention for rheumatoid arthritis via home-based videotaped instructions. Ann Behav Med 2004;27:50–59.
6.
Kelley JE, Lumley MA, Leisen JC: Health effects of emotional disclosure in rheumatoid arthritis patients. Health Psychol 1997;16:331–340.
7.
Wetherell MA, Byrne-Davis L, Dieppe P, Donovan J, Brookes S, Byron M, Vedhara K, Horne R, Weinman J, Miles J: Effects of emotional disclosure on psychological and physiological outcomes in patients with rheumatoid arthritis: an exploratory home-based study. J Health Psychol 2005;10:277–285.
8.
Lepore SJ, Greenberg MA, Bruno M, Smyth JM: Expressive writing and health: self-regulation of emotion-related experience, physiology, and behavior; in Lepore SJ, Smyth JM (eds): The Writing Cure: How Expressive Writing Promotes Health and Emotional Well-Being. Washington, American Psychological Association, 2002, pp 99–117.
9.
Lutgendorf SK, Ullrich P: Cognitive processing, disclosure, and health: psychological and physiological mechanisms; in Lepore SJ, Smyth JM (eds): The Writing Cure: How Expressive Writing Promotes Health and Emotional Well-Being. Washington, American Psychological Association, 2002, pp 177–196.
10.
Sloan DM, Marx BP, Epstein EM: Further examination of the exposure model underlying the efficacy of written emotional disclosure. J Consult Clin Psychol 2005;73:549–554.
11.
Ullrich PM, Lutgendorf SK: Journaling about stressful events: effects of cognitive processing and emotional expression. Ann Behav Med 2002;24:244–250.
12.
Van Zuuren FJ, Schoutrop MJA, Lange A, Louis CM, Slegers JEM: Effective and ineffective ways of writing about traumatic experiences: a qualitative study. Psychother Res 1999;9:363–380.
13.
Booth RJ, Petrie KJ: Emotional expression and health changes: can we identify biological pathways?; in Lepore SJ, Smyth JM (eds): The Writing Cure: How Expressive Writing Promotes Health and Emotional Well-Being. Washington, American Psychological Association, 2002, pp 157–175.
14.
Walker JG, Littlejohn GO, McMurray NE, Cutolo M: Stress system response and rheumatoid arthritis: a multilevel approach. Rheumatology 1999;38:1050–1057.
15.
Arend WP: Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001;45:101–106.
16.
Harbuz MS, Korendowych E, Jessop DS, Crown AL, Lightman SL, Kirwan JR: Hypothalamo-pituitary-adrenal axis dysregulation in patients with rheumatoid arthritis after the dexamethasone/corticotrophin releasing factor test. J Endocrinol 2003;178:55–60.
17.
Van Middendorp H, Sorbi MJ, Van Doornen LJP, Bijlsma JWJ, Geenen R: Feasibility and induced cognitive-emotional change of an emotional disclosure protocol adapted for home application. Patient Educ Couns 2007;66:177–187.
18.
Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Hillsdale, Lawrence Erlbaum Associates, 1988.
19.
Van Middendorp H, Geenen R, Sorbi MJ, Hox JJ, Vingerhoets AJJM, Van Doornen LJP, Bijlsma JWJ: Styles of emotion regulation and their associations with perceived health in patients with rheumatoid arthritis. Ann Behav Med 2005;30:44–53.
20.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–324.
21.
Van Middendorp H, Geenen R: Poor cognitive-emotional processing may impede the outcome of emotional disclosure interventions. Br J Health Psychol 2008;13:49–52.
22.
Pennebaker JW: Writing about emotional experiences as a therapeutic process. Psychol Sci 1997;8:162–166.
23.
Esterling BA, Antoni MH, Fletcher MA, Margulies S, Schneiderman N: Emotional disclosure through writing or speaking modulates latent Epstein-Barr virus antibody titers. J Consult Clin Psychol 1994;62:130–140.
24.
Evers AWM, Taal E, Kraaimaat FW, Jacobs JWG, Abdel Nasser A, Rasker JJ, Bijlsma JW: A comparison of two recently developed health status instruments for patients with arthritis: Dutch-AIMS2 and IRGL. Br J Rheumatol 1998;37:157–164.
25.
Thompson PW, Silman AJ, Kirwan JR, Currey HLF: Articular indices of joint inflammation in rheumatoid arthritis. Arthritis Rheum 1987;30:618–623.
26.
Miki K, Sudo A: Effect of urine pH, storage time, and temperature on stability of catecholamines, cortisol, and creatinine. Clin Chem 1998;44:1759–1762.
27.
Tabachnick BG, Fidell LS: Using Multivariate Statistics, ed 4. Boston, Allyn and Bacon, 2001.
28.
Antoni MH, Cruess DG, Klimas N, Carrico AW, Maher K, Cruess S, Lechner SC, Kumar M, Lutgendorf S, Ironson G, Fletcher MA, Schneiderman N: Increases in a marker of immune system reconstitution are predated by decreases in 24-h urinary cortisol output and depressed mood during a 10-week stress management intervention in symptomatic HIV-infected men. J Psychosom Res 2005;58:3–13.
29.
McCraty R, Barrios Choplin B, Rozman D, Atkinson M, Watkins AD: The impact of a new emotional self-management program on stress, emotions, heart rate variability, DHEA and cortisol. Integr Physiol Behav Sci 1998;33:151–170.
30.
Frattaroli J: Experimental disclosure and its moderators: a meta-analysis. Psychol Bull 2006;132:823–865.
31.
Meads C, Nouwen A: Does emotional disclosure have any effects? A systematic review of the literature with meta-analyses. Int J Technol Assess Health Care 2005;21:153–164.
32.
Greenberg MA, Stone AA: Emotional disclosure about traumas and its relation to health: effects of previous disclosure and trauma severity. J Pers Soc Psychol 1992;63:75–84.
33.
Sloan DM, Marx BP, Epstein EM, Lexington JM: Does altering the writing instructions influence outcome associated with written disclosure? Behav Ther 2007;38:155–168.
34.
Norman SA, Lumley MA, Dooley JA, Diamond MP: For whom does it work? Moderators of the effects of written emotional disclosure in a randomized trial among women with chronic pelvic pain. Psychosom Med 2004;66:174–183.
35.
O’Connor DB, Ashley L: Are alexithymia and emotional characteristics of disclosure associated with blood pressure reactivity and psychological distress following written emotional disclosure? Br J Health Psychol 2008;13:495–512.
36.
Pennebaker JW, Francis ME: Cognitive, emotional, and language processes in disclosure. Cogn Emot 1996;10:601–626.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.